ALNY vs BLCO · P/E 76, rev $1.29B vs rev $5.10B
Alnylam Pharmaceuticals Inc (ALNY) versus Bausch + Lomb Corp (BLCO) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Bausch + Lomb Corp (BLCO) is a medical instruments & supplies company listed on NYSE.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported BLCO revenue for 2025-12-31 was $5.10B. Net income was -$360.0M. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. BLCO currently screens at market cap $5.38B.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. BLCO currently screens at market cap $5.38B.
Not investment advice. Open the ALNY and BLCO stock pages for the full models.
Not investment advice.